VNRX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.480

Open

1.440

VWAP

1.42

Vol

296.39K

Mkt Cap

16.57M

Low

1.335

Amount

419.39K

EV/EBITDA(TTM)

--

Total Shares

11.59M

EV

23.21M

EV/OCF(TTM)

--

P/S(TTM)

2.35

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

Show More

Events Timeline

(ET)

2026-06-17

08:30:00

VolitionRx Partners with Sysmex to Optimize Nu.Q NETs H3.1 Assay

2026-06-03 (ET)

2026-06-03

08:20:00

VolitionRx Expands IP Portfolio with Patent Application for Ebola Monitoring

2026-05-14 (ET)

2026-05-14

16:20:00

Cameron Reynolds: Nu.Q Vet Cat Test to Unlock $5 Million Milestone

2026-05-06 (ET)

2026-05-06

08:20:00

VolitionRx Submits Study on Feline Lymphoma Detection

2026-04-29 (ET)

2026-04-29

08:20:00

VolitionRx Successfully Detects Nucleosomes in Sepsis Patients

2026-04-23 (ET)

2026-04-23

08:20:00

VolitionRx Receives Acceptance of Compliance Plan from NYSE American

2026-03-06 (ET)

2026-03-06

08:20:00

VolitionRx Completes Validation of Nu.Q Vet Cancer Test

News

seekingalpha

06-17seekingalpha

VolitionRx Partners with Sysmex for Diagnostic Optimization

Newsfilter

06-17Newsfilter

VolitionRx Partners with Sysmex to Optimize Nu.Q® NETs Assay

Newsfilter

06-07Newsfilter

VolitionRx Announces Public Offering Plan

Newsfilter

05-27Newsfilter

VolitionRx Reports 300% Q1 Revenue Growth and Key Developments

Yahoo Finance

05-15Yahoo Finance

VolitionRX Reports Significant Q1 2026 Revenue Growth

seekingalpha

05-15seekingalpha

VolitionRx Limited Reports Q1 2026 Earnings with Key Milestones

3 Analyst Rating

Wall Street analysts forecast VNRX stock price to rise

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

1.50

Averages

2.25

High

3.00

Current: 0.000

Low

1.50

Averages

2.25

High

3.00

Maxim

Buy

initiated

$4

AI Analysis

2026-06-18

New

Reason

Maxim

Price Target

$4

AI Analysis

2026-06-18

New

initiated

Buy

Reason

Maxim resumed coverage of VolitionRx with a Buy rating and $4 price target. The company is on track for significant progress across its diagnostic portfolio, including its core franchises: Nu.Q Vet, Nu.Q NETs, and Nu.Q Cancer, and the firm believes the expected progress positions the company for a turnaround and supports partnering discussions to generate shareholder value, the analyst tells investors in a research note.

D. Boral Capital

Buy

to

Hold

downgrade

$NULL

2026-04-20

Reason

D. Boral Capital

Price Target

$NULL

2026-04-20

downgrade

Buy

to

Hold

Reason

D. Boral Capital downgraded VolitionRx to Hold from Buy without a price target citing the company's 1-for-20 reverse stock split, effective April 28. Reverse splits are typically a negative for shareholders because they often signal financial stress, listing pressure, and limited strategic alternatives rather than underlying business strength, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VNRX

Unlock Now

Valuation Metrics

The current forward P/E ratio for VolitionRX Ltd (VNRX.A) is 20.83, compared to its 5-year average forward P/E of -2.28. For a more detailed relative valuation and DCF analysis to assess VolitionRX Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.28

Current PE

20.83

Overvalued PE

2.95

Undervalued PE

-7.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.23

Current EV/EBITDA

-0.82

Overvalued EV/EBITDA

0.29

Undervalued EV/EBITDA

-2.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

56.43

Current PS

2.83

Overvalued PS

146.79

Undervalued PS

-33.93

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

best penny stocks

Intellectia · 65 candidates

Market Cap: <= 300.00MRegion: USPrice: $0.50 - $5.00Volume: >= 100,000Quarter Revenue Yoy Growth: >= 0.0%Gross Margin: >= 0.00Annual Revenue Yoy Growth: >= 0.0%

Ticker

Name

Market Cap$

Interactive Strength Inc

1.87M

Vision Marine Technologies Inc

2.15M

My Size Inc

2.99M

Sonoma Pharmaceuticals Inc

3.96M

Ambow Education Holding Ltd

6.84M

Aclarion Inc

8.08M

all penny stocks out there

Intellectia · 1059 candidates

Region: USPrice: $0.00 - $5.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

iSpecimen Inc

3.23M

Maison Solutions Inc

4.26M

Virax Biolabs Group Ltd

1.10M

Cheetah Net Supply Chain Service Inc (Pre-Reincorporation)

60.78M

VolitionRX Ltd

25.37M

Lixiang Education Holding Co Ltd

3.45M

Intellectia · 4 candidates

Market Cap: 20.00M - 500.00MRegion: USPrice: $0.01 - $0.25List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

NUBURU Inc

29.84M

VolitionRX Ltd

26.28M

KALA BIO Inc

185.00M

Outlook Therapeutics Inc

26.05M

sort list ny market cap

Intellectia · 32 candidates

Price: $0.00 - $0.25Volume: >= 500,000Market Cap Category: micro, nano

Ticker

Name

Market Cap$

KALA BIO Inc

185.00M

Nakamoto Inc

150.98M

Hyperscale Data Inc

62.91M

Srx Health Solutions Inc

45.86M

Atlasclear Holdings Inc

35.12M

NUBURU Inc

29.84M

top penny stocks under $0.25

Intellectia · 32 candidates

Price: $0.00 - $0.25Volume: >= 500,000Market Cap Category: micro, nano

Ticker

Name

Market Cap$

iSpecimen Inc

3.80M

Wellgistics Health Inc

12.58M

zSpace, Inc.

2.85M

Virax Biolabs Group Ltd

1000.00K

Hyperscale Data Inc

62.91M

CXApp Inc

10.40M

What are the top penny stocks under $0.25

Intellectia · 26 candidates

Price: $0.00 - $0.25Volume: >= 500,000Market Cap Category: micro, nanoList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Quince Therapeutics Inc

10.20M

Hyperscale Data Inc

54.64M

Inno Holdings Inc

8.75M

Virax Biolabs Group Ltd

1.11M

Hub Cyber Security Ltd

431.94K

NUBURU Inc

29.16M

penny stocks under $1.00

Intellectia · 330 candidates

Price: $0.00 - $1.00Market Cap Category: micro, nanoList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Jet.AI Inc

9.67M

zSpace, Inc.

3.46M

Quince Therapeutics Inc

4.87M

Cenntro Inc (The Corporation)

10.22M

Hub Cyber Security Ltd

161.60K

Scworx Corp

1.98M

penny stocks positive most active today

Intellectia · 75 candidates

Price: $0.10 - $5.00Volume: >= 1,000,000Price Change Pct: >= $0.10

Ticker

Name

Market Cap$

ICZOOM Group Inc

10.57M

Peloton Interactive Inc

1.88B

Denison Mines Corp

3.08B

Kosmos Energy Ltd

1.73B

Baytex Energy Corp

3.20B

Globavend Holdings Ltd

3.20M

Help me find stocks that are under 2.00

Intellectia · 531 candidates

Region: USPrice: <= $2.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Applied Therapeutics Inc

14.24M

China SXT Pharmaceuticals Inc

11.42M

Jin Medical International Ltd

25.25M

Cenntro Inc (The Corporation)

13.35M

NUBURU Inc

76.36M

urban-gro Inc

3.10M

biotech industry stock under 5 dollars

Intellectia · 282 candidates

Industry: Biotechnology & Medical ResearchPrice: <= $5.00

Ticker

Name

Market Cap$

Applied Therapeutics Inc

14.63M

Theriva Biologics Inc

6.85M

IO Biotech Inc

14.94M

Adial Pharmaceuticals Inc

6.04M

GRI Bio Inc

2.26M

Propanc Biopharma Inc

3.62M

Whales Holding VNRX

Trading Trends

People Also Watch

Frequently Asked Questions

What is VolitionRX Ltd (VNRX) stock price today?

The current price of VNRX is 1.43 USD — it has increased 4.38

What is VolitionRX Ltd (VNRX)'s business?

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

What is the price predicton of VNRX Stock?

Wall Street analysts forecast VNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNRX is2.25 USD with a low forecast of 1.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is VolitionRX Ltd (VNRX)'s revenue for the last quarter?

VolitionRX Ltd revenue for the last quarter amounts to 985.08K USD, increased 299.81

What is VolitionRX Ltd (VNRX)'s earnings per share (EPS) for the last quarter?

VolitionRX Ltd. EPS for the last quarter amounts to -19.37 USD, increased 1629.46

How many employees does VolitionRX Ltd (VNRX). have?

VolitionRX Ltd (VNRX) has 75 emplpoyees as of June 19 2026.

What is VolitionRX Ltd (VNRX) market cap?

Today VNRX has the market capitalization of 16.57M USD.